Cure One opens at LUMC: a major step within the shared innovation pathway of RegMed XB and partners in the field
− 1 min readCure One, a new research centre focused on curative treatments for type 1 diabetes, has officially launched at Leiden University Medical Center (LUMC).
The initiative is supported by LUMC, Stichting DON and the Dutch Diabetes Fund. Although Cure One functions as an independent programme, it is strongly connected to the regenerative medicine technologies and collaborative research developed within RegMed XB.
Building on a shared technological foundation
Over recent years, RegMed XB partners have developed key technologies that now form the scientific foundation for next-generation therapies. Cure One advances these technologies toward clinical readiness, with a strong focus on immune protection and translational development of stem cell-derived islet cells.
Shared expertise across institutions
Several researchers, including Prof. Eelco de Koning and Dr. Françoise Carlotti, contribute to both Cure One and RegMed XB projects. This dual involvement creates a direct bridge between fundamental innovation and clinical translation. This integrated ecosystem accelerates progress toward a durable cure for type 1 diabetes.
Strengthening the wider regenerative medicine landscape
The opening of Cure One reinforces national and regional collaboration across the regenerative medicine field. This alignment enhances capacity for developing and scaling advanced regenerative treatments.
Cure One’s launch marks a meaningful advance for the entire research community working toward curative therapies for type 1 diabetes. It strengthens the continuum from early discovery to technology maturation and, eventually, to clinical testing of stem cell–derived islet cells.
RegMed XB extends congratulations to LUMC, Stichting DON and the Dutch Diabetes Fund on this significant achievement and looks forward to continued progress across the field.